

April 2020

Kyowa Kirin's Response to the COVID-19 Pandemic

Kyowa Kirin Group is implementing responses to the COVID-19 pandemic in accordance with the constantly changing situation in order to fulfill the company's mission as a manufacturer of pharmaceuticals, which is to maintain a continuous supply of quality pharmaceuticals while at the same time giving top priority to minimizing the risk of infection and securing the safety of our employees. The group's current response to COVID-19 pandemic is as follows.

1. Basic policy

While placing top priority on the health and safety of employees working within the group and their significant others, as well as healthcare professionals, patients and their families, Kyowa Kirin is working to keep a stable supply of products available for patients in need. In addition, the company group will keep its attention on preventing the spread of the coronavirus and implement appropriate responses in accordance with the situation.

2. Measures to minimize the risk of infection (Global)

- (1) Employees shall carry out the measures to prevent infection according to policies put in place by governments, organizations and institutions (Washing hands, wearing a mask, social distancing and practicing coughing etiquette).
- (2) Following policies put in place by governments, organizations and institutions, non-manufacturing offices are closed and employees are asked to work from home.
- (3) For work that requires coming to the office, take the appropriate response, such as requiring the employee to measure his or her temperature before coming to the office, working staggered hours, maintaining physical distancing between employees in the office and prohibiting face to face meetings.
- (4) Stop domestic and international business trips, as well as business activities outside the office. However, visits to medical institutions will be carried out only when they are required in order to fulfil the company's responsibilities as a pharmaceutical company.

3. Support provided in response to the increase in COVID-19 infections

- (1) In March 2020, a donation was made to Zhong Nanshan Medical Foundation to support the foundation's activities in China, such as providing financial assistance to afflicted persons and medical assistance focused on respiratory specialists.
- (2) In March and April 2020, the company's active pharmaceutical ingredients (Saxagliptin Hydrate and Medroxyprogesterone acetate) used in the screening of

pharmaceuticals to treat the COVID-19 infections were provided to the National Institute of Infectious Diseases in Japan.

- (3) Across EMEA, Kyowa Kirin are making donations, at a country level, to support local healthcare systems and patients during the COVID-19 pandemic; for example, in April 2020, a donation was made to support the activities of the Red Cross in Spain.
- (4) Kyowa Kirin in EMEA supporting those healthcare professionals, across our business, who are volunteering to assist in front line services in their respective home countries.
- (5) In April 2020, a donation was made to support the activities of AmeriCares, a charitable organization that is currently working to provide Personal Protective Equipment (PPE) and training to health care workers, as well as to maintain care for patients with chronic conditions.
- (6) In April 2020, a donation was made (as part of industry effort) to SAPI (Singapore Association of Pharmaceutical Industries) in Singapore for providing Personal PPE to healthcare institutions. Also, another donation was made in Singapore to the Agency for Integrated Care (AIC) for their Sector Emergency Fund, which supports Nursing Homes Centers, Providers, and Mental Health Providers, and Mental Health Providers for COVID-19 related expenses e.g. disinfecting services and products and PPE.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.